Dundee University Collaboration

RNS Number : 7992X

Physiomics PLC

16 January 2014

 



Physiomics plc

("Physiomics") or ("the Company")

Physiomics to collaborate with the University of Dundee to "optimize drug design and testing" with grant support from the Northern Research Partnership

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a collaboration agreement with the University of Dundee. Physiomics part of the collaboration will be fully funded by the Northern Research Partnership ("NRP") in the form of an "Early Career Researcher Engagement and Exchanges with Business & Industry" agreement.

Under the collaboration agreement, we will collaborate directly with Dr Raluca Eftimie and Dr Fordyce A. Davison to assist them in analysing clinical data with an emphasis on developing new mathematical approaches for drug development. The research project will commence in January 2014.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are pleased to collaborate with such a well know institution in biological modelling. We anticipate that this will further improve our clinical modelling capabilities."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

NRADQLBFZFFFBBF